Yes, sickle cell disease follows an autosomal recessive inheritance pattern. The gene responsible sits on chromosome 11, one of the 22 non-sex chromosomes, which means it affects males and females equally and has nothing to do with the X or Y chromosomes.
What Autosomal Recessive Means
“Autosomal” tells you the gene is on a numbered chromosome, not a sex chromosome. “Recessive” means you need two copies of the altered gene, one from each parent, to develop the disease. A person who inherits only one copy is a carrier, known as having sickle cell trait. Carriers typically have no symptoms but can pass the gene to their children.
The specific mutation is remarkably small. A single letter change in the DNA of the hemoglobin gene swaps one amino acid for another in the protein that carries oxygen through your blood. That one swap causes the hemoglobin to clump together under low-oxygen conditions, distorting red blood cells into the rigid, crescent shape that gives the disease its name.
Inheritance Probabilities for Carriers
When both parents carry sickle cell trait, each pregnancy has the following odds:
- 25% chance the child inherits no sickle cell genes and is completely unaffected
- 50% chance the child inherits one copy and becomes a carrier (sickle cell trait)
- 25% chance the child inherits two copies and has sickle cell disease
These odds reset with every pregnancy. Having one child with the disease does not change the probability for the next. If only one parent carries the trait and the other has two normal copies, none of their children will have sickle cell disease, though half will likely be carriers.
Sickle Cell Trait vs. Sickle Cell Disease
People with sickle cell trait (one normal gene, one sickle gene) produce both normal hemoglobin and the sickle form. The normal hemoglobin is enough to keep red blood cells functioning well under most circumstances, so carriers rarely experience symptoms. They can, however, pass the gene on without ever knowing they carry it unless they’re tested.
Sickle cell disease, the homozygous form where both gene copies are affected, is a different situation entirely. Red blood cells become stiff, sticky, and prone to blocking small blood vessels. This leads to episodes of severe pain, chronic anemia, organ damage over time, and a higher risk of infection. The most common and severe genotype is called HbSS, where both copies carry the sickle mutation. A milder form, HbSC, occurs when a person inherits one sickle gene and one gene for a different hemoglobin variant called hemoglobin C. HbSC patients generally have less severe anemia but face a higher risk of certain complications like eye disease.
Why the Gene Is So Common
A mutation this harmful would normally become rare over time, but sickle cell trait persists at high rates in certain populations because carrying one copy offers significant protection against malaria. The malaria parasite has difficulty growing and multiplying inside red blood cells that contain some sickle hemoglobin. Research in Kenya found that this protection increases with age, peaking at about 56% reduced risk of malaria by age 10.
The protection appears to work on two levels. Sickle trait red blood cells are physically less hospitable to the parasite, and carriers also seem to develop immune responses to malaria faster than people with two normal hemoglobin genes. This survival advantage is why the sickle cell gene is most prevalent in regions where malaria is or was historically common, particularly sub-Saharan Africa. In 2021, an estimated 7.74 million people were living with sickle cell disease globally, with sub-Saharan Africa accounting for nearly 80% of cases.
How It’s Diagnosed
In the United States and many other countries, newborn screening catches sickle cell disease within the first few days of life through a routine blood test. A test called hemoglobin electrophoresis separates the different types of hemoglobin in a blood sample, revealing whether a baby has normal hemoglobin, sickle cell trait, or sickle cell disease. The results also indicate the specific genotype and how severe the condition is likely to be.
For parents who know they’re both carriers, prenatal testing is available as early as 8 to 10 weeks into pregnancy. This can be done using a sample from either the amniotic fluid or the placenta. Unlike newborn screening, which looks for abnormal hemoglobin protein, prenatal testing looks directly at the DNA for the sickle cell gene. Adults who want to know their carrier status before starting a family can request hemoglobin electrophoresis or a genetic test through their healthcare provider. Since carriers almost never have symptoms, testing is the only reliable way to find out.